Coly-Mycin S

Browse PDR's full list of drug information

Coly-Mycin S

Classes

Otic Corticosteroid/anti-infective Combinations

Adverse Reactions
Severe

hearing loss / Delayed / Incidence not known
renal failure (unspecified) / Delayed / Incidence not known
skin atrophy / Delayed / Incidence not known

Moderate

superinfection / Delayed / Incidence not known
contact dermatitis / Delayed / Incidence not known

Mild

pruritus / Rapid / 0-1.0
rash / Early / 0-1.0
skin irritation / Early / Incidence not known
striae / Delayed / Incidence not known
hypertrichosis / Delayed / Incidence not known
miliaria / Delayed / Incidence not known
xerosis / Delayed / Incidence not known
folliculitis / Delayed / Incidence not known
skin hypopigmentation / Delayed / Incidence not known

Common Brand Names

Coly-Mycin S, Cortisporin TC

Dea Class

Rx

Description

Otic, combination antibacterial and antiinflammatory product
Used for treatment of superficial bacterial infections of external auditory canal and infections of mastoidectomy and fenestration cavities caused by susceptible organisms
Use limited to 10 consecutive days due to risk for permanent sensorineural hearing with prolonged neomycin use

Dosage And Indications
For the treatment of superficial bacterial infections of the external auditory canal (i.e., otitis externa) caused by susceptible organisms, and for the treatment of infections of mastoidectomy and fenestration cavities caused by susceptible organisms. Otic dosage Adults

5 drops in affected ear(s) 3 to 4 times daily. Alternatively, insert a cotton wick into the ear canal and saturate with the suspension. Keep the wick moist by adding additional suspension every 4 hours. Replace the wick at least once every 24 hours. Limit the treatment duration to 10 days. If the infection does not improve after 1 week of treatment, cultures should be repeated to verify the identity of the organism and to determine whether therapy should be changed.

Children and Adolescents

4 drops in affected ear(s) 3 to 4 times daily. Alternatively, insert a cotton wick into the ear canal and saturate with the suspension. Keep the wick moist by adding additional suspension every 4 hours. Replace the wick at least once every 24 hours. Limit the treatment duration to 10 days. If the infection does not improve after 1 week of treatment, cultures should be repeated to verify the identity of the organism and to determine whether therapy should be changed.

Dosing Considerations
Hepatic Impairment

No dosage adjustment is needed.

Renal Impairment

No dosage adjustment is needed.

Drug Interactions

There are no drug interactions associated with Colistin; Hydrocortisone; Neomycin; Thonzonium products.

How Supplied

Coly-Mycin S/Neomycin, Colistin Sulfate, Hydrocortisone, Thonzonium Bromide Auricular (Otic) Susp

Maximum Dosage
Adults

Do not exceed 10 days of dosing per treatment course.

Geriatric

Do not exceed 10 days of dosing per treatment course.

Adolescents

Do not exceed 10 days of dosing per treatment course.

Children

Do not exceed 10 days of dosing per treatment course.

Infants

Safety and efficacy not established.

Neonates

Safety and efficacy not established.

Mechanism Of Action

•Colistin: Surface active agent that disrupts the structure of the bacterial cell membrane. Colistin binds in a detergent-like fashion to gram-negative bacterial cell membrane phospholipids by displacing calcium and magnesium. The loss of integrity of the membrane and increased permeability of the cell envelope results in leaking of cell contents and, subsequently, cell death. Colistin also actively binds to the lipid A portion of endotoxin in the outer membrane of gram-negative bacteria, which inactives the endotoxin. The clinical significance of potentially preventing or reducing endotoxin-induced shock is unclear. Colistin has been shown to have bactericidal activity against many aerobic gram-negative organisms by exhibiting 'concentration-dependent killing', which is described as the principle that bactericidal effects increase as the concentration increases.
•Hydrocortisone: Antiinflammatory activity is thought to result from induction of phospholipase A2 inhibitory proteins (lipocortins). These proteins may control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid, which is released from membrane phospholipids by phospholipase A2.
•Neomycin: Neomycin is bacteriocidal. It inhibits bacterial protein synthesis through irreversible binding to the 30S ribosomal subunit of susceptible bacteria. Neomycin is actively transported into the bacterial cell where it binds to receptors present on the 30S ribosomal subunit. This binding interferes with the initiation complex between the messenger RNA (mRNA) and the subunit. As a result, abnormal, nonfunctional proteins are formed due to misreading of the bacterial DNA. Eventually, susceptible bacteria die because of the lack of functional proteins. Neomycin may also inhibit DNA polymerase.
•Thonzonium: Surface active agent that aids in the dispersion and penetration of cellular debris and exudate.

Pharmacokinetics

Colistin, hydrocortisone, neomycin, and thonzonium combination products are applied topically to the ear. Pharmacokinetic data are limited for these combination products.

Other Route(s)

Otic Route
When used as directed, significant systemic concentration of colistin and neomycin are not anticipated; however, increased absorption of neomycin may occur if applied to denuded or damaged epithelium. Topical hydrocortisone is metabolized in the skin. Although, like neomycin, systemic absorption of hydrocortisone may increase if applied to skin that is damage or inflamed.

Pregnancy And Lactation
Pregnancy

Colistin; hydrocortisone; neomycin; thonzonium products are classified as FDA pregnancy risk category C. No adequate and well controlled studies have been conducted in pregnant women, and it is unknown if the drug can cause fetal harm. Aminoglycosides, like neomycin, can cause congenital deafness in humans if administered during pregnancy; however, topically administered neomycin is not expected to produce significant systemic concentrations. In animal studies, corticosteroids, such as hydrocortisone, have been shown to be teratogenic in animals when administered systemically at relatively low doses and after dermal application. For colistin, no embryo/fetal effects were observed when administering doses equivalent to those delivered with otic application. Administer the drug during pregnancy only if the potential benefit justifies the potential risk to the fetus.

The manufacturer recommends that colistin; hydrocortisone; neomycin; thonzonium products be used with caution in women who are breast-feeding. Hydrocortisone and colistin appear in breast milk following oral administration, although it should be noted that there is a minimal possibility of systemic absorption following topical administration. Trace amounts of endogenous hydrocortisone (cortisol) are excreted in breast milk; however, no reports of exogenous hydrocortisone excretion into breast milk exist. The American Academy of Pediatrics (AAP) states that another steroid, prednisone, is usually compatible with breast-feeding. Another report states that systemic steroids used in asthma patients are compatible with breast-feeding. Otic use of neomycin results in minimal systemic absorption. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA.